Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Medigene. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Medigene's earnings available for a low price, and how does
this compare to other companies in the same industry?
Medigene is not considered high growth as it is expected to be loss making for the next 1-3 years.
Medigene's revenue is expected to grow by 5.7% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Medigene's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Prof. Dr. Dolores J. Schendel has been the Chief Executive Officer and Member of Executive Management Board at MediGene AG since February 1, 2016 and May 1, 2014 respectively. Prof. Dr. has been the Chief Scientific Officer at MediGene AG since February 1, 2016. Prof. Dr. Schendel serves as Director of the Institute of Molecular Immunology and Partner at Helmholtz Zentrum München, GmbH. Prof. Dr. Schendel served as Managing Director of trianta Immunotherapies GmbH and holds a professorship in immunology at the ludwig Maximilians university of Munich. Her research focuses on human immunology and immunotherapy. Prof. Dr. Schendel has served as a Member of the German Cancer aid Grants review panel and as Chair of a life Science Study panel of the european research Council.
Dolores's compensation has increased whilst company is loss making.
Dolores's remuneration is about average for companies of similar size in Germany.
Management Team Tenure
Average tenure of the
management team in years:
The average tenure for the Medigene management team is over 5 years, this suggests they are a seasoned and experienced team.
Co-Founder & Chairman of the Supervisory Board
CEO, Chief Scientific Officer & Member of Executive Management Board
Co-Founder & Chairman Scientific Advisory Board
CFO, Chief Business Development Officer and Member of Executive Management Board
Chief Medical Officer
Vice President of Controlling & Accounting
Head of Technology & Innovation
Senior Director and Head of Public & Investor Relations
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Medigene board of directors is less than 3 years, this suggests a new board.
Medigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages. It operates through two segments, Immunotherapies and Other Products. The company develops Dendritic cell vaccines in phase I/II clinical trials; and T-cell receptor-modified T cells and T-cell-specific monoclonal antibodies in preclinical development phase. It also develops Veregen for the treatment of genital warts; and RhuDex for the treatment of autoimmune diseases. Medigene AG has strategic partnership with bluebird bio, Inc. for the development of T cell receptors; and research collaboration agreements with RXi Pharmaceuticals Corporation. The company was founded in 1994 and is headquartered in Munich, Germany.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.